IDSA GUIDELINES Bundle (free trial)

Aspergillosis 2016

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/57608

Contents of this Issue

Navigation

Page 21 of 23

Treatment Table 3. Commonly Encountered Drug-Drug Interactions During Treatment of Aspergillosis (cont'd) Agent/Class Interaction Comment Agents which cause QTc interval prolongation (fluoroquinolone and macrolide antimicrobials, quinine, quinidine, digoxin, amiodarone and other antiarrhythmic drugs, calcium channel blockers, psychiatric drugs, antihistamines, cocaine and other agents) QT interval prolongation, torsades de pointes and other cardiac arrhythmias have been observed with azoles in combination with other agents or preexisting conditions that have these effects. Assess risk benefit and administer with caution to patients with cardiac disorders that increase the risk of arrhythmias. Vincristine and other vinca alkaloid agents • Neurotoxicity including peripheral neuropathy and seizures in combination with azoles. • Azole levels also increased. • Given the potential for serious toxicity, vincristine and other vinca alkaloids should generally not be co-administered with mold-active azoles. • Alternative antifungal therapy (e.g., amphotericin B formulation or echinocandin) should be used. Cyclophosphamide Increased levels with co-administration of some azoles. Increased renal, hepatic or GU dysfunction. 21

Articles in this issue

Archives of this issue

view archives of IDSA GUIDELINES Bundle (free trial) - Aspergillosis 2016